Alcon (ALC) Aktienübersicht
Alcon Inc. erforscht, entwickelt, produziert, vertreibt und verkauft weltweit Augenpflegeprodukte. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
ALC Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alcon Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | CHF 59.38 |
| 52-Wochen-Hoch | CHF 68.34 |
| 52-Wochen-Tief | CHF 47.80 |
| Beta | 0.69 |
| 1 Monat Veränderung | 4.62% |
| 3 Monate Veränderung | 11.62% |
| 1 Jahr Veränderung | -9.43% |
| 3 Jahre Veränderung | -19.74% |
| 5 Jahre Veränderung | -19.69% |
| Veränderung seit IPO | 2.29% |
Aktuelle Nachrichten und Updates
Narrative-Update • Aug 12
ALC: Rich Multiple Will Limit Upside Despite Raised 2026 Earnings Outlook
Analysts have trimmed their Alcon price target by around CHF 2 per share, reflecting slightly more cautious assumptions on revenue growth and valuation multiples, partly offset by marginally firmer profit margin expectations and a small adjustment to the discount rate. What’s in the News for Alcon Alcon reported Q2 results that were ahead of earlier expectations, with revenue up 8% year over year and balanced growth from both the surgical and vision care segments.Narrative-Update • Jul 21
ALC: Buybacks And New Lens Collaboration Will Shape A Measured Outlook
Analysts have trimmed their Alcon price target to CHF56.59 from CHF57.82, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E levels. What's in the News for Alcon Alcon and RxSight entered a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, combining RxSight’s postoperative light-adjustable technology with Alcon’s PCIOL optical designs to allow surgeons to fine-tune vision for cataract patients after surgery.Recent updates
Narrative-Update • Aug 12
ALC: Rich Multiple Will Limit Upside Despite Raised 2026 Earnings Outlook
Analysts have trimmed their Alcon price target by around CHF 2 per share, reflecting slightly more cautious assumptions on revenue growth and valuation multiples, partly offset by marginally firmer profit margin expectations and a small adjustment to the discount rate. What’s in the News for Alcon Alcon reported Q2 results that were ahead of earlier expectations, with revenue up 8% year over year and balanced growth from both the surgical and vision care segments.Narrative-Update • Jul 21
ALC: Buybacks And New Lens Collaboration Will Shape A Measured Outlook
Analysts have trimmed their Alcon price target to CHF56.59 from CHF57.82, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E levels. What's in the News for Alcon Alcon and RxSight entered a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses, combining RxSight’s postoperative light-adjustable technology with Alcon’s PCIOL optical designs to allow surgeons to fine-tune vision for cataract patients after surgery.Narrative-Update • Jul 03
ALC: Share Buybacks And Product Portfolio Expansion Will Shape Measured Outlook
Analysts have raised their price target on Alcon to CHF57.82 from CHF56.34, citing updated assumptions for slightly higher revenue growth, modestly stronger profit margins, and a marginally lower discount rate, along with a broadly similar future P/E outlook. What’s in the News for Alcon Alcon Inc.
Narrative-Update • Jun 19
ALC: Cataract Platform Expansion And Share Buybacks Will Drive Future Upside
Analysts have trimmed their price target on Alcon, with updated fair value estimates moving from around CHF 79.02 to CHF 76.62 as they adjust assumptions for the discount rate, revenue growth, profit margin and future P/E. What’s in the News for Alcon Alcon launched the UNITY CS cataract surgical system in Canada, described as the company’s next generation standalone cataract platform, with a showcase planned at the Canadian Ophthalmological Society Annual Meeting and Exhibition in June 2026, according to Alcon.Narrative-Update • Jun 04
ALC: Share Buybacks And Patent Royalties Will Shape Measured Forward Outlook
Analysts have adjusted their price target on Alcon to reflect updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E, resulting in a revised target of CHF 56.34 compared with the previous CHF 60.81. What's in the News Alcon announced a share repurchase program of up to US$1,500 million, funded by cash generated from operations, with repurchased shares to be cancelled as a return of capital to shareholders; the program is valid for 3 years.
Narrative-Update • May 19
ALC: Share Buybacks And New Eye Care Launches Will Support Upside
Analysts now estimate Alcon's fair value at CHF 88.89, reduced from CHF 92.41, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Board of Directors authorized a share repurchase program of up to US$1,500 million.Narrative-Update • May 04
ALC: New Eye Care Launches Will Support Future Upside Potential
Analysts have nudged their Alcon price target slightly higher to CHF 92.41 from CHF 92.37, reflecting updated assumptions for revenue growth, profit margin and future P/E that leave the overall valuation framework broadly intact. What's in the News Alcon launched Clareon TruPlus, a new enhanced design monofocal and toric intraocular lens in the U.S., adding to its Clareon IOL portfolio and targeting increased depth of focus while maintaining distance vision quality.Narrative-Update • Apr 19
ALC: Contact Lens Expansion And Patent Royalties Will Shape Measured Outlook
Analysts have trimmed their Alcon price target slightly to around CHF61 from about CHF62, reflecting updated assumptions on discount rate, revenue growth, profit margin, and future P/E that are broadly similar to prior estimates. What's in the News Alcon launched Clareon TruPlus monofocal and toric intraocular lenses in the U.S., adding an enhanced design option to the Clareon portfolio that is intended to increase depth of focus while maintaining distance image quality.Narrative-Update • Apr 05
ALC: Future Contact Lens Expansion And Patent Royalties Will Shape Balanced Outlook
Analysts have raised their CHF fair value estimate for Alcon from CHF58.49 to CHF61.63, citing updated assumptions that combine a lower future P/E with a higher projected profit margin. What's in the News Sight Sciences reported that a U.S. District Court order in its patent infringement case preserved a jury verdict that Alcon willfully infringed three patents related to the Hydrus Microstent, with monetary damages of $34 million, plus supplemental damages, interest, and an ongoing 10% royalty on Hydrus revenue through November 10, 2028, subject to final judgment and potential appeal (Key Developments).Narrative-Update • Mar 22
ALC: New Lens Launches And Share Buybacks Will Support Future Outperformance
Analysts have raised their CHF price target for Alcon by roughly CHF 3, reflecting updated assumptions that combine slightly softer revenue growth with higher profit margins and a lower future P/E multiple. What's in the News Alcon launched TOTAL30 Multifocal for Astigmatism in the U.S., described as the only multifocal toric contact lens with Water Gradient Technology aimed at presbyopic patients with astigmatism (Key Developments).Narrative-Update • Mar 08
ALC: Share Repurchases And New Contact Lenses Will Support Upside
Analysts have reduced their Alcon price target to CHF 92.37 from CHF 93.18, reflecting updated views on a slightly higher discount rate, modestly lower revenue growth assumptions, improved profit margin expectations and a lower future P/E multiple. What's in the News Alcon announced the U.S. launch of TOTAL30 Multifocal for Astigmatism, described as the only multifocal toric contact lens with Water Gradient Technology and aimed at patients whose vision needs are shifting toward presbyopia, with lenses now available nationwide through Eye Care Professionals (company announcement).Narrative-Update • Feb 22
ALC: Future Contact Lens Launches Will Balance Margin Pressure Risks
Analysts have reduced their price target on Alcon to about CHF 58.50 from roughly CHF 62.30, citing updated assumptions that combine slightly different revenue expectations with lower projected profit margins and a higher future P/E multiple. What's in the News Alcon launched TOTAL30 Multifocal for Astigmatism in the U.S., described as the only multifocal toric contact lens with Water Gradient Technology, aimed at patients whose vision is shifting toward age related presbyopia and who need comfort through a full month of wear (Key Developments).Narrative-Update • Feb 08
ALC: Weekly Lens Launch And Buybacks Will Support Future Share Outperformance
Analysts have trimmed their price target for Alcon to approximately $75.68 from about $79.76, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Alcon plans a Canadian launch of PRECISION7 sphere and toric one week replacement contact lenses featuring the ACTIV-FLO System, designed to provide 16 hours of comfort and consistent vision through day 7, with commercial availability expected from February 2, 2026 (Key Developments).Narrative-Update • Jan 24
ALC: Ongoing Share Repurchases And Higher Future P/E Will Support Upside
Analysts have modestly trimmed their price target on Alcon by about US$1 to reflect slight adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall view largely intact. What's in the News Alcon completed a share repurchase of 9,301,877 shares, representing 1.89% of its shares, for US$750 million under the buyback announced on February 25, 2025.Narrative-Update • Jan 09
ALC: Share Repurchases And Higher P/E Assumptions Will Support Future Upside
Analysts have nudged their price target on Alcon higher by roughly US$0.26, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers behind the revision. What's in the News Alcon reported impairments of property, plant and equipment and intangible assets of US$2 million for the quarter ended September 30, 2025 (Key Developments).Narrative-Update • Dec 25
ALC: Improved Margins And Buybacks Will Support Stronger Share Performance
Analysts have modestly reduced their price target on Alcon, citing slightly slower projected revenue growth and a higher discount rate that outweigh the benefit of improved margin expectations and a lower future price to earnings multiple. This brings their fair value estimate down by approximately 4.40 dollars per share.Narrative-Update • Dec 11
ALC: Future Surgical Efficiency Gains Will Support Share Outperformance
Analysts have slightly reduced their price target on Alcon to reflect a modestly lower fair value estimate of approximately $79.76. This adjustment comes even as projected revenue growth has been revised marginally higher, because that improvement is offset by a slightly reduced profit margin and an almost unchanged future price-to-earnings multiple.Narrative-Update • Nov 27
ALC: Surgical Workflow Gains Will Drive Share Outperformance In Coming Quarters
Alcon's analyst price target has been raised slightly from $79.92 to $80.15, with analysts citing minor adjustments to revenue growth and profit margin assumptions as the primary drivers of this upward revision. What's in the News Alcon announced $2 million in impairments of property, plant and equipment, and intangible assets for the quarter ending September 30, 2025.Analyseartikel • Nov 14
Alcon Inc. (VTX:ALC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Alcon Inc. ( VTX:ALC ) had a good week, as its shares rose 5.9% to close at CHF62.88 following the release...Narrative-Update • Nov 12
ALC: Surgical Efficiency Gains Will Drive Share Momentum Ahead
Narrative Update: Alcon Analyst Price Target Revision Analysts have raised their price target for Alcon from $79.17 to $79.92. This revision is based on updated valuation models that reflect modest adjustments in discount rates and forward profit expectations.Narrative-Update • Oct 27
Cutting Edge Eye Care Solutions Will Transform Outcomes For Global Aging Populations
Alcon's analyst price target has been revised slightly downward, decreasing by $1.25 to $79.17. Analysts have adjusted their expectations to reflect slightly lower revenue growth and profit margin forecasts.Narrative-Update • Oct 13
Global Aging And Emerging Markets Will Expand Eye Care
Analysts have slightly reduced their price target for Alcon from $81.30 to $80.43, citing cautious adjustments to growth and profit margin expectations. What's in the News Alcon announced results from multiple time and motion studies showing its UNITY Vitreoretinal Cataract System (VCS) achieves up to 16% efficiency gain in workflow compared to other leading vision systems, with significant reductions in setup and tear-down times.Narrative-Update • Aug 23
Unity VCS And PRECISION7 Launches Will Strengthen Position In Eye Care Market
Alcon's consensus price target has been revised downward, primarily reflecting a significantly lower future P/E multiple despite improved revenue growth forecasts, resulting in a new fair value estimate of CHF82.40. What's in the News Alcon updated 2025 net sales guidance to $10.3–$10.4 billion, slightly down from the previous $10.4–$10.5 billion, while reaffirming Core diluted EPS at $3.05–$3.15.
Neues Narrative • Mar 19
Unity VCS And PRECISION7 Launches Will Strengthen Position In Eye Care Market
Alcon's broad product pipeline and innovations in Surgical, Vision Care, and Ocular Health are positioned to propel revenue growth.Aktionärsrenditen
| ALC | CH Medical Equipment | CH Markt | |
|---|---|---|---|
| 7D | 0.3% | -1.0% | -1.6% |
| 1Y | -9.4% | -6.7% | 14.7% |
Rendite im Vergleich zur Industrie: ALC unter dem Niveau der Branche Swiss Medical Equipment , die im vergangenen Jahr eine Rendite von -6.7% erzielte.
Rendite vs. Markt: ALC hinter dem Markt Swiss zurück, der im vergangenen Jahr eine Rendite von 14.7 erzielte.
Preisvolatilität
| ALC volatility | |
|---|---|
| ALC Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 3.8% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 2.1% |
Stabiler Aktienkurs: ALC hatte in den letzten 3 Monaten im Vergleich zum Swiss -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: ALCDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1945 | 25,000 | David Endicott | www.alcon.com |
Alcon Inc. erforscht, entwickelt, produziert, vertreibt und verkauft Augenpflegeprodukte weltweit. Das Unternehmen ist in zwei Segmenten tätig: Chirurgie und Vision Care. Es bietet Geräte, Instrumente und Diagnostika, Intraokularlinsen (IOLs) und andere Implantate sowie Verbrauchsmaterialien wie Viskoelastika, chirurgische Lösungen, Inzisionsinstrumente, chirurgische Spezialpackungen und andere Produkte für chirurgische Verfahren an.
Alcon Inc.'s Grundlagenzusammenfassung
| ALC grundlegende Statistiken | |
|---|---|
| Marktanteil | CHF 28.70b |
| Gewinn(TTM) | CHF 512.64m |
| Umsatz(TTM) | CHF 8.66b |
56.0x
Kurs-Gewinn-Verhältnis 3.3x
Kurs-Umsatz-VerhältnisIst ALC zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ALC Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$10.86b |
| Kosten der Einnahmen | US$4.65b |
| Bruttogewinn | US$6.22b |
| Sonstige Ausgaben | US$5.57b |
| Gewinn | US$643.00m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
Nov 11, 2026
| Gewinn per Aktie (EPS) | 1.33 |
| Bruttomarge | 57.22% |
| Nettogewinnspanne | 5.92% |
| Schulden/Eigenkapital-Verhältnis | 21.9% |
Wie hat sich ALC auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.5%
Aktuelle Dividendenrendite27%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/19 23:53 |
| Aktienkurs zum Tagesende | 2026/08/19 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Alcon Inc. wird von 59 Analysten beobachtet. 23 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | Argus Research Company |
| Jeffrey Johnson | Baird |
| null null | Baird |